title: Strategies to stabilize compact folding and minimize aggregation of antibody-based fragments.
abstract: Monoclonal antibodies (mAbs) have proven to be useful for development of new therapeutic drugs and diagnostic techniques. To overcome the difficulties posed by their complex structure and folding, reduce undesired immunogenicity, and improve pharmacokinetic properties, a plethora of different Ab fragments have been developed. These include recombinant Fab and Fv segments that can display improved properties over those of the original mAbs upon which they are based. Antibody (Ab) fragments such as Fabs, scFvs, diabodies, and nanobodies, all contain the variable Ig domains responsible for binding to specific antigenic epitopes, allowing for specific targeting of pathological cells and/or molecules. These fragments can be easier to produce, purify and refold than a full Ab, and due to their smaller size they can be well absorbed and distributed into target tissues. However, the physicochemical and structural properties of the immunoglobulin (Ig) domain, upon which the folding and conformation of all these Ab fragments is based, can limit the stability of Ab-based drugs. The Ig domain is fairly sensitive to unfolding and aggregation when produced out of the structural context of an intact Ab molecule. When unfolded, Ab fragments may lose their specificity as well as establish non-native interactions leading to protein aggregation. Aggregated antibody fragments display altered pharmacokinetic and immunogenic properties that can augment their toxicity. Therefore, much effort has been placed in understanding the factors impacting the stability of Ig folding at two different levels: 1) intrinsically, by studying the effects of the amino acid sequence on Ig folding; 2) extrinsically, by determining the environmental conditions that may influence the stability of Ig folding. In this review we will describe the structure of the Ig domain, and the factors that impact its stability, to set the context for the different approaches currently used to achieve stable recombinant Ig domains when pursuing the development of Ab fragment-based biotechnologies.
authors: Department of Immunology, Mayo Clinic College of Medicine, Rochester, USA.
authors: Diana
authors: D
authors: Gil
authors: Department of Immunology, Mayo Clinic College of Medicine, Rochester, USA.
authors: Adam G
authors: AG
authors: Schrum
keywords: Aggregation; Antibody; Conformation; Fab; Fragment; Immunoglobulin; Osmolyte; Protein Folding; Therapy
references: Nature. 1989 Oct 12;341(6242):544-6
references: 2677748
references: J Pharm Sci. 1996 Apr;85(4):419-26
references: 8901081
references: Adv Exp Med Biol. 2012;747:137-52
references: 22949116
references: Amino Acids. 2007 Nov;33(4):587-605
references: 17357829
references: Protein Eng Des Sel. 2012 Oct;25(10):591-601
references: 22843678
references: J Mol Biol. 2005 Sep 23;352(3):597-607
references: 16095608
references: Appl Microbiol Biotechnol. 2007 Nov;77(1):13-22
references: 17704915
references: Biotechnol J. 2011 Jan;6(1):38-44
references: 20949542
references: Nature. 1993 Jun 3;363(6428):446-8
references: 8502296
references: J Pharm Sci. 2007 Jan;96(1):1-26
references: 16998873
references: J Exp Biol. 2005 Aug;208(Pt 15):2819-30
references: 16043587
references: J Mol Biol. 1994 Sep 30;242(4):309-20
references: 7932691
references: Science. 2003 Jun 27;300(5628):2065-71
references: 12829775
references: Oncogene. 2007 May 28;26(25):3734-44
references: 17530026
references: Nature. 1975 Aug 7;256(5517):495-7
references: 1172191
references: Biochemistry. 1992 Oct 20;31(41):9857-64
references: 1390769
references: Biochem Soc Trans. 1983 Apr;11(2):130-2
references: 6662267
references: Curr Protoc Protein Sci. 2002 May;Chapter 4:Unit 4.6
references: 18429236
references: Pharm Res. 2003 Sep;20(9):1325-36
references: 14567625
references: FEBS Lett. 1995 Dec 18;377(2):135-9
references: 8543036
references: J Biotechnol. 2001 Jun;74(4):277-302
references: 11526908
references: Proteins. 2011 Sep;79(9):2637-47
references: 21732420
references: Int J Cancer. 2002 Mar 20;98(3):456-62
references: 11920600
references: Science. 1988 Oct 21;242(4877):423-6
references: 3140379
references: J Mol Biol. 2005 Apr 8;347(4):773-89
references: 15769469
references: Nat Rev Immunol. 2007 Aug;7(8):622-32
references: 17641665
references: Curr Opin Struct Biol. 2009 Feb;19(1):39-49
references: 19162470
references: MAbs. 2009 Jan-Feb;1(1):26-8
references: 20046570
references: J Mol Biol. 2003 Sep 19;332(3):643-55
references: 12963373
references: FEBS Lett. 1999 Dec 3;462(3):307-12
references: 10622716
references: Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):13997-4002
references: 16968772
references: Immunotechnology. 1997 Jun;3(2):83-105
references: 9237094
references: Protein Eng Des Sel. 2010 Jul;23(7):549-57
references: 20457695
references: Biochemistry. 1998 Sep 15;37(37):12918-26
references: 9737871
references: Protein Sci. 2000 Feb;9(2):344-52
references: 10716186
references: J Biol Chem. 2009 Jan 30;284(5):3273-3284
references: 19010777
references: Biochemistry. 2002 Mar 19;41(11):3628-36
references: 11888279
references: Nat Biotechnol. 2005 Sep;23(9):1126-36
references: 16151406
references: Annu Rev Chem Biomol Eng. 2012;3:263-86
references: 22468604
references: Nat Biotechnol. 2005 Sep;23(9):1137-46
references: 16151407
references: J Mol Biol. 2004 Apr 2;337(4):893-903
references: 15033359
references: J Mol Biol. 2001 Feb 2;305(5):989-1010
references: 11162109
references: J Biol Chem. 2008 Feb 8;283(6):3639-3654
references: 18045863
references: Nat Med. 2003 Jan;9(1):129-34
references: 12514726
references: Int J Pharm. 2006 Mar 9;310(1-2):175-86
references: 16427224
references: Pharm Res. 1996 Apr;13(4):643-6
references: 8710761
references: Methods. 2004 Oct;34(2):184-99
references: 15312672
references: Nat Rev Immunol. 2003 Feb;3(2):123-32
references: 12563296
references: J Mol Biol. 2003 Jan 31;325(5):979-89
references: 12527303
references: Adv Drug Deliv Rev. 2006 Aug 7;58(5-6):686-706
references: 16839640
references: J Mol Biol. 2001 Jul 27;310(5):955-63
references: 11502004
references: Proc Natl Acad Sci U S A. 1988 Aug;85(16):5879-83
references: 3045807
references: Methods Mol Biol. 2012;911:3-13
references: 22886242
references: Med Microbiol Immunol. 2009 Aug;198(3):157-74
references: 19529959
references: Curr Opin Biotechnol. 2000 Feb;11(1):81-4
references: 10679348
references: Methods Mol Biol. 2012;911:15-26
references: 22886243
references: J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S41-52
references: 20176268
references: Methods Mol Biol. 2012;907:537-56
references: 22907373
references: FASEB J. 1992 Oct;6(13):3207-17
references: 1397843
references: Biochemistry. 1990 Feb 13;29(6):1362-7
references: 2110478
references: J Biol Chem. 2012 Dec 14;287(51):42936-50
references: 23109335
references: Biomol Eng. 2001 Oct 15;18(3):95-108
references: 11566601
references: Appl Environ Microbiol. 2000 Apr;66(4):1572-9
references: 10742244
references: Nat Biotechnol. 2002 Dec;20(12):1189-90
references: 12454662
references: FEBS Lett. 1995 Mar 6;360(3):247-50
references: 7883041
references: Protein Eng. 1999 Jul;12(7):563-71
references: 10436082
references: J Immunol Methods. 1999 Dec 10;231(1-2):25-38
references: 10648925
references: Nat Struct Biol. 1996 Sep;3(9):803-11
references: 8784355
references: Proc Natl Acad Sci U S A. 2006 Sep 5;103(36):13357-61
references: 16899544
references: Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7538-42
references: 8356052
references: Am J Physiol. 1986 Aug;251(2 Pt 2):R197-213
references: 3017133
references: Immunol Invest. 2011;40(3):299-338
references: 21244216
references: Methods. 2004 Nov;34(3):312-22
references: 15325649
references: Arch Biochem Biophys. 2009 Nov;491(1-2):1-6
references: 19769937
references: Trends Biochem Sci. 2001 Apr;26(4):230-5
references: 11295555
references: Yakugaku Zasshi. 2003 Nov;123(11):957-61
references: 14631757
references: Protein Eng. 1997 Apr;10(4):435-44
references: 9194169
references: AAPS J. 2012 Sep;14(3):554-8
references: 22610647
references: Arthritis Rheum. 2006 Jun;54(6):1856-66
references: 16736523
references: Ann N Y Acad Sci. 1995 Sep 29;764:242-60
references: 7486531
references: Annu Rev Immunol. 1988;6:381-405
references: 3289571
references: Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6444-8
references: 8341653
references: Microb Cell Fact. 2011 Jun 09;10:44
references: 21658216
references: Structure. 2004 Aug;12(8):1339-41
references: 15296726
references: Protein Eng. 1994 Sep;7(9):1129-35
references: 7831284
references: Protein Eng Des Sel. 2010 Aug;23(8):643-51
references: 20543007
references: Science. 1982 Sep 24;217(4566):1214-22
references: 7112124
references: Pharm Res. 2003 Dec;20(12):1952-60
references: 14725359
references: Biophys J. 1985 Mar;47(3):411-4
references: 3978211
references: Curr Opin Pharmacol. 2008 Oct;8(5):600-8
references: 18691671
references: Acta Pharmacol Sin. 2005 Jun;26(6):649-58
references: 15916729
references: Expert Opin Drug Deliv. 2006 Jan;3(1):53-70
references: 16370940
references: IUBMB Life. 2010 Dec;62(12):891-5
references: 21190292
references: Pharm Res. 1995 Oct;12(10):1447-52
references: 8584478